Stock RIGL RIGEL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665596034

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
1.05 USD -1.87% Intraday chart for Rigel Pharmaceuticals, Inc. -7.89% -27.59%
Apr. 12 Rigel Pharmaceuticals, Inc. Enters into Amendment No. 4 to that Certain Credit and Security Agreement CI
Mar. 12 Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer CI

Evolution of the average Target Price on Rigel Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6c40741cd5dc1.bC0fxEZabU1BdD2GSyv687Y1ZP3qb-cKam4amZ3I-2I.BFgqtHQWCgE3B0mrOFKYp9d2Ar-NHK8_CTxSrPeFzDs8H1f3EzwHH3ANbA~16aa1118291b1f3f90524da9c811f56e

Analyst Recommendations on Rigel Pharmaceuticals, Inc.

Citigroup Adjusts Rigel Pharmaceuticals' Price Target to $4 From $3, Maintains Buy Rating MT
B. Riley Lifts Rigel Pharmaceuticals' PT to $1.75 From $1.25 After Announced Purchase of US Rights to Gavreto From Blueprint Medicines; Keeps Neutral Rating MT
B. Riley Trims Rigel Pharmaceuticals' PT to $1.25 From $1.75, Lowers Peak Sales Estimate for Rezlidhia; Maintains Neutral Rating MT
Piper Sandler Assumes Neutral Rating on Rigel Pharmaceuticals With $2 Price Target MT
Citigroup Adjusts Price Target on Rigel Pharmaceuticals to $3 From $2, Keeps Buy Rating MT
Health Care Up as Rate Fears Weigh -- Health Care Roundup DJ
Citigroup Upgrades Rigel Pharmaceuticals to Buy From Neutral, Raises Price Target to $2 From $1.50 MT
HC Wainwright Adjusts Rigel Pharmaceuticals' Price Target to $15 from $7, Keeps Buy Rating MT
Piper Sandler Adjusts Price Target on Rigel Pharmaceuticals to $2 From $1, Maintains Neutral Rating MT
Cantor Fitzgerald Raises Rigel Pharmaceuticals Price Target to $2 From $1, Maintains Neutral Rating MT
BMO Lowers Rigel Pharmaceuticals' Price Target to $3 From $7, Maintains Outperform Rating MT
B. Riley Lowers Rigel Pharmaceuticals' Price Target to $1.25 from $4 After Disappointing Trial Data on Fostamatinib, Keeps Neutral Rating MT
Citigroup Downgrades Rigel Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $0.80 From $7 MT
Piper Sandler Cuts Rigel Pharmaceuticals to Neutral From Overweight, Price Target to $1 From $7 MT
Jefferies Lowers Rigel Pharmaceuticals to Hold From Buy, Price Target to $1 From $8 MT
HC Wainwright Adjusts Rigel Pharmaceuticals' Price Target to $7 from $11, Keeps Buy Rating MT
Cantor Fitzgerald Downgrades Rigel Pharmaceuticals to Neutral from Overweight MT
B. Riley Initiates Rigel Pharmaceuticals at Neutral with $4 Price Target, Notes Hidden Risks in Phase III Protocol for Warm Autoimmune Hemolytic Anemia MT
RIGEL PHARMACEUTICALS : JPMorgan Downgrades Rigel Pharmaceuticals to Neutral From Overweight MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.05 USD
Average target price
4.567 USD
Spread / Average Target
+334.92%
High Price Target
15 USD
Spread / Highest target
+1,328.57%
Low Price Target
1.65 USD
Spread / Lowest Target
+57.14%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Rigel Pharmaceuticals, Inc.

Citigroup
B. Riley
Piper Sandler
HC Wainwright
Cantor Fitzgerald
Jefferies & Co.
BMO Capital

Ratings for Rigel Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RIGL Stock
  4. Consensus Rigel Pharmaceuticals, Inc.